BINV — BioInvent International AB Share News
0.000.00%
Last trade - 00:00- SEK1.59bn
- SEK1.14bn
- SEK226.50m
Brief: Transgene And Bioinvent Receive CTA Approval For Phase 1/2A Trial Of Oncolytic Virus BT-001 In Solid Tumors
Brief: Bioinvent And Cantargia Sign Manufacturing Agreement For Monoclonal Antibody CAN10
Brief: BioInvent Q3 Loss After Tax Narrows To SEK 32.9 Million
CASI Pharma: Rises on deal with BioInvent to develop, market cancer drug
Brief: BioInvent Gets EUR 2 Mln Milestone Payment From Daiichi Sankyo
Brief: BioInvent Q2 Loss After Tax Widens To SEK 39.3 Mln
Brief: Bioinvent Sek 139 Million Rights Issue Heavily Oversubscribed
Brief: BioInvent International: BI-1206 Could Improve Treatment In Several Cancers
Brief: Bioinvent to launch SEK 139 mln repair rights issue
Brief: Finansinspektionen Says Van Herk Investments B.V. Increases Stake In Bioinvent
Brief: Bioinvent International Extends Research Collaboration And License Agreement With Pfizer Inc.
Swedish stocks: Seen opening slightly higher
Brief: BioInvent Successfully Completes Directed Share Issue Of About SEK 487 Mln
Brief: Bioinvent Enters New Production Deal With American Company
Brief: Bioinvent Q1 Loss After Tax Widens To SEK 32.6 Million
Brief: Bioinvent: Promising Progress In Phase I/LLA Trial Of Lead Program BI-1206 In Combination With Rituximab
Brief: Bioinvent Postpones The AGM
Brief: BioInvent And Skylinedx To Collaborate On Patient Stratification To Maximize Impact Of Treatment With BI-1206
Brief: BioInvent And Transgene Presents Data About BT-001